rporate social responsibility (CSR), will make available interactive and easy-to access online training solutions for ACRES Global Platform of services. This CSR commitment, mirrored by ACRES, is exemplified in Astra Nova’s Better Industry Initiative (Bii), which provides free and commercial high-quality training courses and other resources, with an ultimate goal of better serving patients by equipping future and current industry professionals with more refined skills and workflow efficiency tools.
With Astra Nova, ACRES will provide timely information on critical training topics and materials needed globally, and they will partner on Learning Management Systems development. Other collaborative efforts involve jointly organizing multi-stakeholder events dedicated to improving the conduct of clinical research globally.
Astra Nova’s Business Development Director, Ms. Maya Zlatanova, said: “Our main goal is to improve patient safety and allow easier access to industry regulations, standards, and knowledge. We believe that everyone will benefit from this partnership, and the results of this collaboration will become visible in the very first days of establishing it.”
Dr Matthew Whalen, COO of ACRES, noted, “ACRES work is conducted through alliances, and Astra Nova brings added depth to ACRES network of organizations committed to transforming the world of clinical research.” Whalen added, “We are looking forward to working together with Astra Nova in a variety of ways to realize our shared collaboration goal of providing more innovative solutions, broader standardization, better quality of service, greater safety, and increased efficiency.”
ASTRA NOVA LTD:
More information on Astra Nova’s work can be found here. For more information, please contact Ms. Maya Zlatanova at
Page: 1 2 3 Related biology technology :1
Copyright©2014 Vocus, Inc.
All rights reserved
. Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments2
. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline3
. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others4
. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma5
. Top Five Global Cardiovascular Drug Companies 2013 Report Features Players such as Pfizer and AstraZeneca6
. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting7
. Isis Pharmaceuticals Earns $10 Million Milestone Payment from AstraZeneca for ISIS-AR Rx to Treat Prostate Cancer8
. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment9
. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey10
. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients11
. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation